1.
|
Phase: Phase II Type: Prevention Status: Active Age: 30 to 69 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: 10587, CFEM345AUS45, 5R01CA122577-03, NCT00579826
|
|
2.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 18 to 50 Sponsor: NCI Protocol IDs: SWOG-S0812, S0812, NCT01097278
|
|
3.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 25 and over Sponsor: NCI, Other Protocol IDs: 08218, R01CA140245-01, NCI-2010-01976, NCT01196936
|
|
4.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: Postmenopausal Sponsor: NCI Protocol IDs: NCI-2011-00949, 09-0869-04, CDR0000666604, UARIZ-09-0869-04, UARIZ-UAZ08-12-02, NCT01077453
|
|
5.
|
Phase: No phase specified Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000581219, P30CA015083, MC0536, 06-002061, MAYO-MC0536, NCT00611104
|
|
6.
|
Phase: No phase specified Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 20 to 40 Sponsor: NCI, Other Protocol IDs: CDR0000597679, FCCC-06827, 06-827, NCT00700778
|
|
7.
|
Phase: No phase specified Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 55 and under Sponsor: NCI Protocol IDs: CALGB-70806, CALGB 70806, NCT01224678
|
|
8.
|
Phase: No phase specified Type: Diagnostic, Prevention, Treatment Status: Active Age: 30 to 75 Sponsor: NCI, Other Protocol IDs: 1B-10-6, NCI-2010-01847, NCT01219075
|